CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
ATI-502drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03585296
NCT03585296Phase 2Completed
CompareCT.gov

A Phase 2 Safety Study of ATI-502 Topical Solution in Subjects With Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc.·interventional·Posted Jul 13, 2018·Updated Feb 17, 2020

In Brief

A Phase 2 clinical trial evaluating ATI-502 for Atopic Dermatitis. Completed, enrolled 22 participants across 6 sites.

Detailed Summary

This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD). Subjects will be required to apply ATI-502 study medication to their identified AD treatment areas. All subjects will be required to complete a safety follow up visit 4 weeks post last study medication application

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 13, 2018
Enrollment StartJul 10, 2018
Primary CompletionApr 25, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.0 years ago

Interventions

ATI-502drug

Topical Solution